Molecular and clinical characterization of HER2-low versus HER2-0 breast cancer

Comparison of genomic profiles and survival outcomes between HER2-low and HER2-0 subtypes

INDICATION
Breast
BIOMARKER
HER2

 

 

Top: ERBB2 RNA expression in HER2-0, HER2-low, and HER2+ patients. Bottom: UMAP of mutation data (excluding ERBB2) colored by HER2-0, HER2-low, or HER2+ status, utilizing the Tempus xT 648-gene panel. Analysis is restricted to considering the presence of pathogenic alterations.

 

Related cases

Icon with three vertical bars and a circle, resembling a bar graph or LinkedIn logo.Lens Library
Three abstract data distributions displayed as shapes made of small, colored squares.

Sacituzumab govitecan and tumor microenvironment shifts in metastatic triple-negative breast cancer

2026-07-01
CXCL/SPP1 (CS)
Breast
Icon with three vertical bars and a circle, resembling a bar graph or LinkedIn logo.Lens Library
Abstract data visualization showing a grid of blue, black, and brown dots in patterns.

TP53 mutations are enriched in HER2-positive biliary tract cancer and drive poor outcomes

2026-07-01
Biliary Tract Cancer
TP53
HER2
Icon with three vertical bars and a circle, resembling a bar graph or LinkedIn logo.Lens Library
A blue grid with dark blue squares forming a descending diagonal path, possibly a heatmap.

Optimizing therapy sequencing for HR+ HER2- metastatic breast cancer

2026-05-26
Breast
HER2